Table 5 Comparison of adverse events between cisplatin combined with IL-2 versus cisplatin alone

Changjie H 2001 [15]

30

30

–

–

–

–

13

43.3

0

0

–

–

–

–

10

33.3

0

0

Xiuzhi Y 2001 [16]

40

20

14

35

11

55

5

12.5

5

25

–

–

–

–

–

–

–

–

Zhuo S 2004 [17]

32

30

3

9.3

3

10

5

15.6

4

13.3

–

–

–

–

–

–

–

–

Junyan W 2005 [18]

48

34

–

–

–

–

12

25

8

23.5

–

–

–

–

18

37.5

11

32.4

Haiying X 2009 [19]

35

28

3

9

8

28.6

8

22.9

9

32.1

–

–

–

–

12

36.4

1

4

Xiaoxia H 2009 [20]

37

35

13

35.1

10

25

11

29.7

11

31.4

–

–

–

–

4

10.8

3

8.6

Lizheng C 2009 [21]

46

40

–

–

–

–

–

–

–

–

12

26.1

4

10

–

–

–

–

Jinguang C 2009 [22]

31

31

–

–

–

–

6

20

8

26

5

16

3

10

6

19

2

6

Junfeng W 2010 [23]

41

41

–

–

–

–

19

46.4

21

51.2

6

14.6

8

19.5

21

51.2

15

36.3

Jingping Z 2010 [24]

63

61

4

6.3

3

4.9

7

11.1

2

3.3

12

19.5

9

14.8

13

20.6

4

6.6

Cheng X 2010 [25]

41

41

6

19.4

8

25.8

11

35.5

7

26.6

7

22.6

4

12.9

9

29

7

26.6

Fang S 2011 [26]

30

30

2

6.6

3

10

4

13.3

6

20

7

23.3

5

16.6

12

40

9

30

Yan Q 2011 [28]

34

34

2

4.8

2

5.7

2

4.8

3

8.6

5

12.2

6

17.1

3

7.3

4

11.4

Li J 2013 [29]

41

35

16

42.1

13

37.1

9

23.7

8

22.8

6

15.8

4

11.4

2

7.1

3

8.5

Lijie H 2014 [30]

38

35

3

10

3

10

3

10

3

10

4

13.3

3

10

6

20

3

10

Miao H 2016 [31]

30

30

4

12.9

5

16.6

11

35.5

10

33.3

24

77.4

20

66.6

–

–

–

–